I am a highly motivated commercial professional with over 25 years' experience with a successful track record of wealth creation in commercialising life science technologies through deals including partnering of products and technologies and venture financing focusing on patient impact.Both scientifically and legally qualified, as a non-practising barrister, with board level and executive management experience allowing me to think differently and be more strategic.At the Crick I lead all commercial translation activity including spinning out Adendra Therapeutics with Apple Tree Partners for $53m, where she is the Crick’s Board Observer.Previous roles include being on the executive team of Abzena plc as SVP IP Commercial and Legal Affairs, where I concluded partnering deals worth over $700m bio dollars plus royalties and was COO and executive board member of Stabilitech.At UCL, I led BioPharm Technology Transfer and was instrumental in starting BioVex with the academic founders, securing the first three rounds of funding. BioVex was sold to Amgen for $1 billion and the product is on the market.
Listed skills include Biotechnology, Technology Transfer, Business Development, Lifesciences, and 16 others.